• Core testing volumes up 90% YoY, on track for >24,000 core tests in FY26
• Microbiome Explorer test sales up 70% in Australia, 3,200% in UK vs PCP
• Invivo branded supplements set record quarter, up 110% in UK vs PCP

Microba Life Sciences Limited (ASX: MAP) reported a strong Q2 FY26, with core testing volumes up 90% year-over-year and the company on track to exceed 24,000 core tests in FY26. In Australia, the company saw record quarterly sales growth, with Microbiome Explorer test sales up 70% versus the prior corresponding period (PCP) and an annualised run-rate of 17,440 tests sold. In the UK, the company continued to make good progress, with Microbiome Explorer test sales up 3,200% versus PCP. The company's supplement business also performed well, with Invivo branded supplements setting a record quarter, including a 110% increase in PHGG prebiotic supplement sales versus PCP in the UK. The company completed a major Microba brand update in November 2025, consolidating its global brands and improving operational efficiency and marketing effectiveness. This has already resulted in a reduction in the time from practitioner signup to first referral, from 12.4 days to 1.7 days. The company also highlighted progress in its AI implementation, with an AI-powered customer support agent resolving 71.4% of inquiries autonomously with a 94.7% customer satisfaction score.

Microba is on track to meet its regional break-even guidance by the end of FY26.